Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox Purchases 100,000 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CEO John Cox purchased 100,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the acquisition, the chief executive officer directly owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded up $1.05 on Wednesday, hitting $9.33. 5,449,458 shares of the company were exchanged, compared to its average volume of 1,909,069. The company's 50 day moving average price is $11.28 and its two-hundred day moving average price is $12.50. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.60 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Caitong International Asset Management Co. Ltd boosted its position in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after acquiring an additional 2,446 shares in the last quarter. Quarry LP acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $50,000. E Fund Management Co. Ltd. boosted its position in shares of Dyne Therapeutics by 16.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Optimize Financial Inc acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $154,000. Institutional investors own 96.68% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DYN. Sanford C. Bernstein began coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price target on the stock. Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Tuesday, June 17th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Raymond James Financial initiated coverage on shares of Dyne Therapeutics in a report on Wednesday, June 11th. They set an "outperform" rating and a $37.00 price target on the stock. Finally, Jones Trading initiated coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They issued a "buy" rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.63.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.